[2] Wardrop D., Keeling D. "The story of the discovery of heparin and warfarin". Oxford Haemophilia and Thrombosis Centre, Oxford Radcliffe Hospitals, Oxford, UK. Junho de 2008.

 

[3] Glurich I, Burmester JK, Caldwell MD. "Understanding the pharmacogenetic approach to warfarin dosing". Springer Science+Business Media, LLC 2008. 8 de Novembro de 2008

 

[4] Hardman, J.G., L.E. Limbird, P.B., A.G. Gilman. "Goodman and Gilman's The Pharmacological Basis of Therapeutics". 10th ed. New York, NY: McGraw-Hill, 2001

 

[5] Juliana Souto Teles, Ellen Yukie Fukuda, David Feder. “Warfarin: pharmacological profile and drug interactions with antidepressants”. Einstein (São Paulo). 2012

 

[6] http://www.drugs.com/pro/warfarin.html

​

[7] Deacon, R. M. Hyponeophagia: A Measure of Anxiety in the Mouse. J. Vis. Exp. (51), e2613, doi:10.3791/2613 (2011)

[8] University of California, http://animalscience.ucdavis.edu/avian/pfs23.htm, acedido em 10-05-2013

 

[9] Pamela, J.W. “Patient Factors That Influence Warfarine Dose Response”. Journal of Pharmacy Practice, 23 (3), 194-204 (2010)

​

[10] Nutescu, E., Chuatrisorn, I.,Hellenbart, E. “Drug and dietary Interactions of Warfarin and novel oral anticoagulants: an update”. Journal of Thrombosis and Thrombolysis,  31, 326-343 (2011)

​

​[11] http://www.aacc.org/members/nacb/NACBBlog/lists/posts/post.aspx?ID=98#, acesso 03-05-2013

​

[12] Pamela, J.W. “Patient Factors That Influence Warfarine Dose Response”. Journal of Pharmacy Practice, 23 (3), 194-204 (2010)

​

[13] Tadors, R., Shakib, S. “Warfarin indications, risks and drug interactions”. Australian Family Phisician”, 39 (7), 476-479 (2010)

​

[14] Teles, J.S., Fukuda, E.Y., Feder, D. “Warfarin: pharmacological profile and drug interactions with antidepressants”. Einstein (São Paulo), 10 (1): 110-105 (2012)

​

[15] Moreau C, Loriot MA, Siguret V. Les antagonistes de la vitamine K : de leur découverte à la pharmacogénétique. Ann Biol Clin 2012 ; 70(5) : 539-51 doi:10.1684/abc.2012.0740

​

[16] Kamali F, Wynne H. "Pharmacogenetics of warfarin". Institute of Cellular Medicine, Newcastle University, Newcastle Upon Tyne, UK.Annu Rev Med. 2010

​

[17] Resumo das Características do Medicamento (RCM) da Varafrina http://www.infarmed.pt/infomed/download_ficheiro.php?med_id=9007&tipo_doc=rcm

​